Based on tonic BCR signaling-dependent DLBCL model, Szydlowski et al. demonstrated that SYK inhibition decreases AKT activity and eventually leads to FOXO1-mediated cell death [56]. The gene discussed is AKT1; the disease is diffuse large B-cell lymphoma.